Subcutaneous · GLP-1 / GIP dual
VK2735
5 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
5
Ongoing
2
Recruiting
0
Completed
3
Sites
149
Countries
3
Endpoints
12
Composite endpoints
5
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Top 20 metrics across this asset's endpoints
4
3
1
1
1
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
5 of 5
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| VANQUISH 1VK2735 for Weight Management Phase 3 | VK2735 Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 137 | Jul 2027 | - | |
| NCT07104383VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | VK2735 Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Active, not recruiting | 127 | Jul 2027 | - | |
| VENTUREVK2735 for Weight Management Phase 2 | VK2735 Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 20 | Feb 2024 | 1 | |
| NCT06828055VK2735 for Weight Management Phase 2 (Venture Oral Dosing) | VK2735 Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 15 | Jun 2025 | - | |
| NCT05203237Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 | VK2735 Healthy volunteers, Obesity / overweight | Healthy volunteers | Ph 1 | Completed | 1 | Nov 2024 | - |
Showing 1-5 of 5 trials